yes, but randomization does not guarantee equivalency of all variables at baseline. its not uncommon for a few baseline parameters to still be skewed despite others being evenly split. the baseline is just such an easy thing to show in the graph that i found it surprising they didnt include it since it would clearly drive home the point of efti's MOA being clinically confirmed.
anyway, i messaged marc and hope he is able to confirm the baseline cd8 was the same for both groups - any pharma partner/acquirer would require this information
otherwise, presentation looks great!
Ann: Immutep Corporate Presentation, page-15
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.005(1.61%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 31.5¢ | 30.8¢ | $149.6K | 479.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 269028 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 213387 | 11 |
View Market Depth
| Last trade - 11.08am 12/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |